{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-0.21","upperLimit":"-0.05","value":"-0.113"},{"groupId":"OG002","lowerLimit":"0.00","upperLimit":"0.00","value":"0.000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-0.14","upperLimit":"0.36","value":"0.107"},{"groupId":"OG002","lowerLimit":"0.10","upperLimit":"0.10","value":"0.100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"-0.08","upperLimit":"0.23","value":"0.050"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.10","upperLimit":"0.10","value":"0.100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 6 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"0.10","value":"0.100"},{"groupId":"OG001","lowerLimit":"0.27","upperLimit":"1.68","value":"0.678"},{"groupId":"OG002","lowerLimit":"0.68","upperLimit":"1.91","value":"1.223"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"End of Study Intervention"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Change from baseline in serum monoclonal (M)-protein level was measured by using electrophoresis at Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 and end of study intervention.","dispersionType":"Full Range","groups":[{"description":"Participants received M3258 at a dose of 10 milligrams (mg) orally, once daily (QD) until disease progression.","id":"OG000","title":"M3258 10 mg QD"},{"description":"Participants received M3258 at a dose of 10 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG001","title":"M3258 10 mg Twice Per Week"},{"description":"Participants received M3258 at a dose of 20 mg orally, twice per week on Day 1 and Day 4 until disease progression.","id":"OG002","title":"M3258 20 mg Twice Per Week"}],"paramType":"MEAN","populationDescription":"Safety analysis set included all participants who were administered any dose of the trial medication. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"Number Analyzed\" signifies those participants who were evaluable for specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1 and end of study intervention (Week 20.1) (each Cycle is of 28 days)","title":"Part A: Change From Baseline in Serum Monoclonal (M)-Protein Level Measured Using Electrophoresis","type":"SECONDARY","unitOfMeasure":"gram per deciliter (g/dL)"}